Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
about
Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancerClinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.Targeting and limiting surgery for patients with node-positive breast cancer.An update in breast cancer screening and management.Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-AnalysisPatterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance).Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (AllBreast-conserving Surgery Rates in Breast Cancer Patients With Different Molecular Subtypes: An Observational Study Based on Surveillance, Epidemiology, and End Results (SEER) Database.Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.Outcome after neoadjuvant chemotherapy in Asian breast cancer patients.Evaluation of a Marker Clip System in Sonographically Guided Core Needle Biopsy for Breast Cancer Localization Before and After Neoadjuvant ChemotherapyLandmark clinical trials influencing surgical management of non-invasive and invasive breast cancer.Role of imaging in neoadjuvant therapy for breast cancer.Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.Expanding the Indications for Total Skin-Sparing Mastectomy: Is It Safe for Patients with Locally Advanced Disease?Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy.Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members.Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer.Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review.Trends and controversies in multidisciplinary care of the patient with breast cancer.Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012.Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).A Prospective Study on Skin-Sparing Mastectomy for Immediate Breast Reconstruction with Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy in Invasive Breast Carcinoma.The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer.Localizing the Clipped Node in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Early Learning Experience and Challenges.Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer.Surgical Management of Breast Cancer Treated with Neoadjuvant Therapy
P2860
Q28066481-D6C44003-DEAB-4360-8151-60704D78C722Q33766513-9754FEEA-8830-4848-8815-8DA1450B0AC0Q35673614-7B8BD7C2-31DB-40CA-B6B1-6BFA9F6C810BQ35874123-885B6A20-C830-4B95-97C4-F00380661ABAQ36118278-979FBF58-4291-466D-93B9-26AABBAAE90BQ36577603-8A39515F-9711-4660-8AB5-DC80D691E7ABQ36649784-9FD6BA55-9DE7-4E62-8802-2AE85BBE2798Q36653521-3C0BDC21-A070-4579-88A2-AB626FE10D0BQ37176151-41A45DC1-3022-47BD-B878-05AB391AF972Q37609483-A48527A9-ACBC-499A-84F4-A1B91F468B6CQ37709871-1D993510-0C08-47A4-990A-7E9535444C61Q38292852-2DE5B8DF-3F3C-45D3-86E0-B1BA2D2185A7Q38366386-1B4D8C60-0CAA-4673-BFEE-55806E6490CEQ38409756-FD749512-8258-4CAC-877B-7E917A7A487DQ38546419-A9C2E9D9-7080-4137-9AF1-5E551DF1E26FQ38635564-A8D130E1-F3E9-4EE4-87AE-978059B30A87Q38647498-309173B5-CE1D-4E5A-B650-EFACC4A8D0B4Q38696564-A947CB3D-8990-4DCE-AE9D-6B6B0C071E79Q38704901-788EFA95-5018-4003-9A66-C0004227F046Q39029485-6FB2602B-3098-4C0A-9C08-74E6C526BFDDQ39119467-9F83C4FF-7813-49D8-B690-C0AA92631DECQ39407066-1D167CBA-1730-47CD-AD6B-03BF44A6EB1CQ39568666-9434FA71-A06F-4DC0-AE1F-FCB2ADD5C500Q39936888-F741A6B1-6384-43B8-99C2-A3A02698680AQ40100099-DCF18D83-A0AD-44CD-9192-89150895F5DDQ40179607-F1DC03BB-76D3-4925-AF1B-4D3606163C66Q40361140-05734AE2-0177-47D7-A819-92E8C5C1E4AFQ40763024-77C4F5FD-9E5A-4552-8201-481CF1A7919DQ41632698-114F4E1C-2802-4266-BD79-485FBE6FD680Q47838863-22CF3CB8-3D31-4562-8E54-A6DA7DE376ECQ50060384-1460893B-87F8-4E19-820E-3BFEE3A42410Q50431199-1B6F109F-6654-425B-8AF9-3A4C78D7A84DQ53095851-705C2BFF-5BAD-436A-9B81-F1C6AFD2AB78Q55000673-39D3B215-D651-42FE-80EE-C3016742D1DDQ57495769-27456FBE-29A5-4424-BFED-4F6903B29FF1
P2860
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tumor biology correlates with ...... ve Multicenter Clinical Trial.
@ast
Tumor biology correlates with ...... ve Multicenter Clinical Trial.
@en
Tumor biology correlates with ...... findings from the ACOSOG Z1071
@nl
type
label
Tumor biology correlates with ...... ve Multicenter Clinical Trial.
@ast
Tumor biology correlates with ...... ve Multicenter Clinical Trial.
@en
Tumor biology correlates with ...... findings from the ACOSOG Z1071
@nl
prefLabel
Tumor biology correlates with ...... ve Multicenter Clinical Trial.
@ast
Tumor biology correlates with ...... ve Multicenter Clinical Trial.
@en
Tumor biology correlates with ...... findings from the ACOSOG Z1071
@nl
P2093
P2860
P1433
P1476
Tumor biology correlates with ...... ive Multicenter Clinical Trial
@en
P2093
A Marilyn Leitch
Bret Taback
Elizabeth A Mittendorf
Gretchen M Ahrendt
Judy C Boughey
Kelly K Hunt
Lee G Wilke
Linda M McCall
Teresa Flippo-Morton
P2860
P304
608-14; discussion 614-6
P356
10.1097/SLA.0000000000000924
P407
P577
2014-10-01T00:00:00Z